title: [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
abstract: The aim of this study was to examine the feasibility of short volume hydration (SH) with magnesium and mannitol versus normal high volume hydration (NH) for targeting nephrotoxicity in lung cancer patients treated with cisplatin (CDDP)- containing chemotherapy. Between January 2012 and February 2013, 28 patients with lung cancer at a single institute received CDDP-containing chemotherapy. We retrospectively evaluated the incidence of nephrotoxicity during the first cycle of chemotherapy. Nephrotoxicity was compared between the SH and NH regimens according to the Common Terminology Criteria for Adverse Events(CTCAE) version 4.0. Laboratory data were collected from the 2 regimen groups at pre-treatment, during the first cycle, and post-treatment and were compared by univariate analysis. Twelve patients received the SH regimen with magnesium and mannitol, and 16 patients received the NH regimen. Only 1 patient in the NH regimen group had Grade 2 increases in serum creatinine. On the other hand, no patient in the SH regimen group had increased serum creatinine. There was no significant difference in the incidence of nephrotoxicity between the 2 regimen groups during the first cycle of CDDP induction(p=0.38). The SH regimen with magnesium and mannitol is feasible in lung cancer patients treated with CDDP-containing chemotherapy.
authors.affiliation: Dept. of Medical Oncology, KKR Sapporo Medical Center.
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Ohhara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Isobe
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Ito
authors.forename: Satoshi
authors.initials: S
authors.lastname: Fuke
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Kojima
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Saito
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nishiura
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005240:Feasibility Studies; D005260:Female; D005440:Fluid Therapy; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control / Q000628:therapy*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D002945:Cisplatin